Qurient Announces U.S. FDA Clearance of IND Application for Q702, a Novel Cancer Immunotherapy
Phase 1 clinical study in patients with advanced solid tumor expected to start in 3Q2020 SEONGNAM-SI, Korea–(BUSINESS WIRE)–#Qurient—Qurient Co. Ltd.…
Pharmaceuticals, Biotechnology and Life Sciences
Phase 1 clinical study in patients with advanced solid tumor expected to start in 3Q2020 SEONGNAM-SI, Korea–(BUSINESS WIRE)–#Qurient—Qurient Co. Ltd.…
Launched from Versant’s Ridgeline Discovery Engine Based on work from Rajesh Chopra, Ian Collins and Nicolas Thomä, leaders in ubiquitin…
Launched from Versant’s Ridgeline Discovery Engine Based on work from Rajesh Chopra, Ian Collins and Nicolas Thomä, leaders in ubiquitin…
— FDA Sets PDUFA Goal Date of October 30, 2020 — WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company…
— FDA Sets PDUFA Goal Date of October 30, 2020 — WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company…
— FDA Sets PDUFA Goal Date of October 30, 2020 — WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Ribon Therapeutics, a clinical stage oncology company developing first-in-class therapeutics targeting stress response pathways, today announced that Victoria…
— PDUFA Date Set for December 3, 2020 — CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics…